227 related articles for article (PubMed ID: 30896812)
1. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
Lee HR; Baek KH
Oncol Rep; 2019 May; 41(5):2625-2635. PubMed ID: 30896812
[TBL] [Abstract][Full Text] [Related]
2. Allelic Polymorphisms of
Ureshino H; Shindo T; Kojima H; Kusunoki Y; Miyazaki Y; Tanaka H; Saji H; Kawaguchi A; Kimura S
Cancer Immunol Res; 2018 Jun; 6(6):745-754. PubMed ID: 29695383
[TBL] [Abstract][Full Text] [Related]
3. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study.
Varbanova VP; Mihailova S; Naumova E; Mihaylova AP
Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191
[TBL] [Abstract][Full Text] [Related]
4. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
5. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
6. Allelic polymorphisms of
Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
[TBL] [Abstract][Full Text] [Related]
7. The role of KIR positive NK cells in diseases and its importance in clinical intervention.
Dizaji Asl K; Velaei K; Rafat A; Tayefi Nasrabadi H; Movassaghpour AA; Mahdavi M; Nozad Charoudeh H
Int Immunopharmacol; 2021 Mar; 92():107361. PubMed ID: 33429335
[TBL] [Abstract][Full Text] [Related]
8. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.
Sconocchia G; Lau M; Provenzano M; Rezvani K; Wongsena W; Fujiwara H; Hensel N; Melenhorst J; Li J; Ferrone S; Barrett AJ
Blood; 2005 Nov; 106(10):3666-72. PubMed ID: 16046526
[TBL] [Abstract][Full Text] [Related]
9. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
Hallner A; Bernson E; Hussein BA; Ewald Sander F; Brune M; Aurelius J; Martner A; Hellstrand K; Thorén FB
Blood; 2019 Mar; 133(13):1479-1488. PubMed ID: 30647027
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
11. HLA and KIR polymorphisms affect NK-cell anti-tumor activity.
Passweg JR; Huard B; Tiercy JM; Roosnek E
Trends Immunol; 2007 Oct; 28(10):437-41. PubMed ID: 17825623
[TBL] [Abstract][Full Text] [Related]
12. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
[TBL] [Abstract][Full Text] [Related]
13. NK cell killer Ig-like receptor repertoire acquisition and maturation are strongly modulated by HLA class I molecules.
Sleiman M; Brons NH; Kaoma T; Dogu F; Villa-Forte A; Lenoble P; Hentges F; Kotsch K; Gadola SD; Vilches C; Zimmer J
J Immunol; 2014 Mar; 192(6):2602-10. PubMed ID: 24554773
[TBL] [Abstract][Full Text] [Related]
14. Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells.
Holubova M; Leba M; Gmucova H; Caputo VS; Jindra P; Lysak D
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311121
[TBL] [Abstract][Full Text] [Related]
15. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
16. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
17. NK cell receptors and their ligands in leukemia.
Verheyden S; Demanet C
Leukemia; 2008 Feb; 22(2):249-57. PubMed ID: 18046448
[TBL] [Abstract][Full Text] [Related]
18. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
19. Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies.
Varbanova V; Naumova E; Mihaylova A
Cancer Immunol Immunother; 2016 Apr; 65(4):427-40. PubMed ID: 26874942
[TBL] [Abstract][Full Text] [Related]
20. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
